Provention faces delay in FDA review of diabetes prevention antibodyThe FDA says it has uncovered “deficiencies” in the marketing application for Provention Bio’s much-anticipated drug teplizumab for Share XProvention faces delay in FDA review of diabetes prevention antibodyhttps://pharmaphorum.com/news/provention-faces-delay-in-fda-review-of-diabetes-prevention-antibody/
Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hopeTwo antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir Biotech, can Share XLilly and GSK/Vir antibody pairing offers resistant COVID-19 hopehttps://pharmaphorum.com/news/lilly-and-gsk-vir-antibody-pairing-offers-resistant-covid-19-hope/
COVID-19 drives Boehringer’s R&D spend to record level in 2020Boehringer Ingelheim invested €3.7 billion on R&D last year, the highest spend in its history, as it mobilised Share XCOVID-19 drives Boehringer’s R&D spend to record level in 2020https://pharmaphorum.com/news/covid-19-drives-boehringers-rd-spend-to-record-level-in-2020/
AZ deploys mobile sites to test COVID-19 antibody AZD7442AstraZeneca is playing catch up with Eli Lilly and Regeneron with its antibody therapy for COVID-19, but aims Share XAZ deploys mobile sites to test COVID-19 antibody AZD7442https://pharmaphorum.com/news/az-deploys-mobile-sites-to-test-covid-19-antibody-azd7442/
Y-mAbs claims FDA OK for neuroblastoma drug DanyelzaY-mAbs Therapeutics has claimed its first product approval, getting a green light from the FDA for Danyelza for Share XY-mAbs claims FDA OK for neuroblastoma drug Danyelzahttps://pharmaphorum.com/news/y-mabs-claims-fda-ok-for-neuroblastoma-drug-danyelza/
Lilly to ship COVID-19 drug straight away after FDA green lightEli Lilly has said it will start shipping supplies of its COVID-19 drug bamlanivimab immediately, after claiming emergency-use Share XLilly to ship COVID-19 drug straight away after FDA green lighthttps://pharmaphorum.com/news/lilly-to-ship-covid-19-drug-straight-away-after-fda-green-light/
Regeneron’s COVID-19 antibody cocktail therapy hits safety problemRegeneron’s coronavirus antibody cocktail therapy against COVID-19, famously used to treat president Donald Trump, has hit a safety Share XRegeneron’s COVID-19 antibody cocktail therapy hits safety problemhttps://pharmaphorum.com/news/regenerons-covid-19-antibody-cocktail-therapy-hits-safety-problem/
US buys Lilly COVID antibody, as effectiveness questions remainThe US government said it will buy 300,000 doses of Eli Lilly’s COVID-19 therapy bamlanivimab for $375 million Share XUS buys Lilly COVID antibody, as effectiveness questions remainhttps://pharmaphorum.com/news/us-buys-300000-doses-lilly-covid-antibody/
NIAID drops Lilly antibody from ACTIV-3 COVID-19 trialEli Lilly says no more patients will be treated with its COVID-19 therapy bamlanivimab in a trial run Share XNIAID drops Lilly antibody from ACTIV-3 COVID-19 trialhttps://pharmaphorum.com/news/niaid-drops-lilly-antibody-from-activ-3-covid-19-trial/
